Comparison of clinical outcomes between androgen deprivation therapy with up-front abiraterone and bicalutamide for Japanese patients with LATITUDE high-risk prostate cancer in a real-world retrospective analysis.
Taku NaikiKiyoshi TakaharaToshiki ItoKeita NakaneYosuke SugiyamaTakuya KoieRyoichi ShirokiHideaki MiyakeTakahiro YasuiPublished in: International journal of clinical oncology (2021)
In patients with LATITUDE high-risk mCSPC, upfront use of Abi combined with ADT resulted in favorable prognostic outcomes compared with conventional ADT with Bica.